Loading…
Decoy Therapeutics Inc. is projected to decline to $6.47 by 2027, a -20% move from its current price of $8.05. DCOY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.59 | $8.05 | $8.54 | -0.01% |
| May 30 | $7.40 | $8.05 | $8.75 | -0.02% |
| May 31 | $7.27 | $8.05 | $8.91 | -0.03% |
| Jun 1 | $7.15 | $8.05 | $9.05 | -0.04% |
| Jun 2 | $7.05 | $8.05 | $9.18 | -0.05% |
| Jun 3 | $6.96 | $8.04 | $9.30 | -0.06% |
| Jun 4 | $6.88 | $8.04 | $9.40 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.88 | $8.04 | $9.40 | -0.07% |
| Week 2 | $6.45 | $8.04 | $10.02 | -0.15% |
| Week 3 | $6.13 | $8.03 | $10.53 | -0.22% |
| Week 4 | $5.87 | $8.03 | $10.97 | -0.30% |
| Week 5 | $5.66 | $8.02 | $11.37 | -0.37% |
| Week 6 | $5.47 | $8.01 | $11.75 | -0.45% |
| Week 7 | $5.30 | $8.01 | $12.10 | -0.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools.
The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics targeting infectious diseases and oncology.
The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Decoy Therapeutics Inc. (DCOY) is currently trading at $8.05 with a market cap of $4.28M and a rank of 5312. These figures place the stock among a broad spectrum of small-cap healthcare names.
Near-term price prospects align with a neutral view, while the longer horizon shows meaningful upside according to the forecast. The model projects a path of gradual growth with higher upper bounds in the later years, reflecting evolving expectations for the company’s peptide conjugate platform and oncology/infectious disease focus.
A major floor 60.3% below — a decisive break under it would weaken the trend.
The nearest floor, 45.2% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 35.7% above — clearing it would confirm fresh momentum.
Key DCOY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DCOY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.99 | Buy | $7.11 | Buy |
| MA 10 | $5.87 | Buy | $6.45 | Buy |
| MA 20 | $5.80 | Buy | $6.07 | Buy |
| MA 50 | $6.13 | Buy | $6.54 | Buy |
| MA 100 | $7.52 | Buy | $11.91 | Sell |
| MA 200 | $23.60 | Sell | $45.58 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 73.43 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 216.82 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.37 | Buy |
| ROC (12) | 40.73 | Buy |
| Bollinger %B (20,2) | 1.09 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | 1.20 | Buy |
| Ultimate (7,14,28) | 86.37 | Sell |
| Momentum (10) | 2.90 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 8.16 | Sell |
| ADX (14) | 27.01 | Buy |
| ATR (14) | 0.33 | Info |
The 30-day technical picture is Neutral overall. The RSI(14) sits at 70, indicating a potentially stretched short-term momentum but not an explicit overbought signal given the neutral sentiment.
SMA50 is $6.13 and SMA200 is $23.60, placing near-term momentum in a nuanced zone between the two moving averages. On the price levels, support is $4.41 and resistance is $8.05. The 30-day price range runs from $5.46 to $11.88, highlighting a relatively wide swing over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.41 | $8.05 | $9.06 | 0% | Neutral | |
| $4.66 | $6.47 | $9.73 | -20% | Bearish | |
| $4.78 | $7.05 | $11.26 | -12% | Neutral | |
| $5.14 | $7.98 | $13.38 | -1% | Neutral | |
| $5.93 | $9.65 | $16.82 | +20% | Neutral | |
| $5.66 | $9.62 | $17.35 | +20% | Neutral | |
| $5.19 | $9.20 | $17.11 | +14% | Neutral | |
| $4.41 | $8.14 | $15.54 | +1% | Neutral | |
| $3.79 | $7.28 | $14.25 | -10% | Neutral | |
| $5.07 | $10.11 | $20.26 | +26% | Bullish | |
| $5.04 | $11.21 | $24.65 | +39% | Bullish | |
| $9.72 | $21.59 | $49.66 | +168% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.41 | $8.05 | $9.48 | +0.00% |
| June 2026 | $6.40 | $7.68 | $9.54 | -4.59% |
| July 2026 | $6.54 | $7.97 | $10.16 | +3.80% |
| August 2026 | $6.35 | $7.85 | $10.20 | -1.53% |
| September 2026 | $5.66 | $7.08 | $9.34 | -9.88% |
| October 2026 | $5.37 | $6.78 | $9.07 | -4.20% |
| November 2026 | $5.46 | $6.96 | $9.42 | +2.64% |
| December 2026 | $5.15 | $6.61 | $9.06 | -4.93% |
Click any year to see its month-by-month DCOY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The DCOY price prediction for 2026 points to an average of $8.05 (low $4.41, high $9.06) — a potential gain of 0% on today's $8.05. Price action looks broadly range-bound.
In 2027, DCOY is projected to trade between $4.66 and $9.73, averaging $6.47 — a potential decline of -20% from today's $8.05. That is -20% versus the projected 2026 average. Expect choppier, lower action through this leg of the cycle.
Decoy Therapeutics Inc.'s 2028 outlook centres on $7.05, within a $4.78 to $11.26 range. That is up +9% on the projected 2027 average. That marks a -12% change versus current levels. Price action looks broadly range-bound.
By 2029, DCOY could reach as high as $13.38, with a base case around $7.98 and support toward $5.14 — roughly -1% from $8.05. A consolidation phase looks the most probable path here.
Expect DCOY to range from $5.93 to $16.82 through 2030. The $9.65 average target implies a +20% move from current prices. That is up +21% on the projected 2029 average. Price action looks broadly range-bound.
The DCOY price prediction for 2031 points to an average of $9.62 (low $5.66, high $17.35) — a potential gain of +20% on today's $8.05. A consolidation phase looks the most probable path here.
In 2032, DCOY is projected to trade between $5.19 and $17.11, averaging $9.20 — a potential gain of +14% from today's $8.05. That is -4% versus the projected 2031 average. Price action looks broadly range-bound.
Decoy Therapeutics Inc.'s 2033 outlook centres on $8.14, within a $4.41 to $15.54 range. That is -12% versus the projected 2032 average. That marks a +1% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, DCOY could reach as high as $14.25, with a base case around $7.28 and support toward $3.79 — roughly -10% from $8.05. Price action looks broadly range-bound.
Expect DCOY to range from $5.07 to $20.26 through 2035. The $10.11 average target implies a +26% move from current prices. That is up +39% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The DCOY price prediction for 2040 points to an average of $11.21 (low $5.04, high $24.65) — a potential gain of +39% on today's $8.05. Momentum favours further upside here.
In 2050, DCOY is projected to trade between $9.72 and $49.66, averaging $21.59 — a potential gain of +168% from today's $8.05. That is up +93% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in DCOY today (≈ 124.223602 DCOY) could be worth
$2,682.31
+$1,682.31 (+168%) by 2050 · US Dollar
Based on the average projected DCOY price of $21.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DCOYwould be worth at today's price.
$1,000 invested in DCOY on May 27, 2025 (≈ 6.65336 DCOY) would be worth
$53.56
-$946.44 (-94.6%) today · 0.05× · US Dollar
Based on a DCOY entry price of $150.3 vs. today's $8.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.56 | $1,447.84 | +44.8% |
| 1 month ago | $5.51 | $1,460.98 | +46.1% |
| 3 months ago | $8.2 | $982.19 | -1.8% |
| 6 months ago | $11.28 | $713.65 | -28.6% |
| 1 year ago | $150.3 | $53.56 | -94.6% |
| All time (5.0y) ago | $45,720 | $0.18 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DCOY forecast.
Our base-case forecast reaches $16.00 around 2050.
Implied market cap at $16.00: $8.51M
The multi-year forecast shows a generally bullish tilt emerging in the later years, with notable upside in 2030, 2040, and 2050. In 2030 the average price is projected at $9.65 with a max of $16.82 and a min of $5.93, delivering an ROI of 19.9% and a neutral sentiment.
By 2035 the average climbs to $10.11 with a max of $20.26 and an ROI of 25.6%, with a bullish read emerging. The 2040 forecast sits at an average of $11.21 (max $24.65) and an ROI of 39.2%, continuing the bullish stance. By 2050 the average is $21.59 (max $49.66) with an ROI of 168.2% and a bullish sentiment.
The forecast also shows intermittently negative periods earlier in the forecast horizon (for example, 2027: avg $6.47, ROI −19.6%; 2028: avg $7.05, ROI −12.5%; 2029: avg $7.98, ROI −0.8%), underscoring the volatility implied by the path ahead. The drivers cited include the IMP3ACT platform’s focus on infectious diseases and oncology, which underpin the longer-run upside while acknowledging near-term volatility.
Tap a question to reveal the answer.
2030 min $5.93, avg $9.65, max $16.82; ROI 19.9%; sentiment NEUTRAL.
The forecast shows mixed early years with some negative ROIs (e.g., 2027 −19.6%, 2028 −12.5%), but gains are projected later, with 2030 avg $9.65, 2040 avg $11.21, and 2050 avg $21.59 with a 168.2% ROI. Sentiment shifts to bullish in the later years.
The forecast maximum by 2050 is $49.66, which is just under $50.
2027 min $4.66, avg $6.47, max $9.73 with ROI −19.6% and a BEARISH sentiment.
Current price $8.05; Market cap $4.28M.
Decoy Therapeutics Inc. Community Discussion
0Share your Decoy Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.